Stock Ratings / Health Care / ECOR / insiders

OM (35) HYPR (45) STXS (30) NRXS (32) ⌘ Pro Terminal →

electroCore Inc. (ECOR) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$8.11 -3.68% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $8.04

electroCore Inc. (ECOR) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $73.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $8.04 (-0.85%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.8% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ECOR)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (38/100 Composite)

🔍 WHY ECOR SCORES 38/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (26% of score)

FRED Regime × Technicals: 45% of 52W Range • RSI-14 at 37.5 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$9.66-18.7% Next Q

Q2 (-2Q)

Grade D$7.85-10.2% Next Q

Q3 (-1Q)

Grade D$7.05+15% Next Q

Current

Grade D-$8.11-7.8% Hist 90D α

Trajectory: D (46) → D- (38)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ECOR Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ECOR currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($9.49) and Max Pain ($8.52) forces dealer call-delta covering toward $13.33.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ECOR• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ECOR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 38%NO 62%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

ECOR Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (ECOR)

No recent open-market Form 4 cluster sales or emergency dumps flagged on ECOR. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ECOR)

✓Walkthrough of ECOR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ECOR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +24.58%▲ ASCENDING CHANNEL

2026-10-30O $7.76H $8.54L $7.49C $8.11VOL 63.8K

RES: $13.54SUP: $7.11SMA50: $9.49SMA200: $7.74

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ECOR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ECOR Butterfly Map → + Track ECOR →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +27.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ECOR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ECOR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ECOR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ECOR)

Health Care Rank #721 of 1016 ⚔️ OM vs ECOR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ECOR vs. OM, HYPR, STXS, NRXS)

Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus (26 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, electroCore Inc. (ECOR) ranks #721 by composite RQD confidence (38/100, grade D-) and #701 by equity capitalization ($73.1M). Within this direct 5-issuer industry benchmark cohort, ECOR leads on earnings valuation at N/A trailing P/E, while OM leads on capital efficiency and profitability with -28.0% ROIC and 39.1% gross margin. HYPR currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with ECOR at 38/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ECOR ACTIVE electroCore Inc.	D-	38/100	—	86.8%	-35.0%	-3.68%	$73.1M	Benchmark Subject
OM Outset Medical Inc.	D-	35/100	—	39.1%	-28.0%	-3.46%	$78.8M	/om-vs-ecor →
HYPR Hyperfine Inc. (Class A)	D	45/100	—	49.8%	-35.0%	-5.23%	$78.9M	/hypr-vs-ecor →
STXS Stereotaxis Inc.	E	30/100	—	52.7%	-35.0%	-6.21%	$91.2M	/stxs-vs-ecor →
NRXS Neuraxis Inc.	E	32/100	—	84.2%	-35.0%	-0.26%	$94.8M	/nrxs-vs-ecor →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001560258

In its most recent audited fiscal period (FY2025, filed 2025-12-31), electroCore Inc. (ECOR) reported GAAP revenue of $32.0M (+27.2% vs. FY2024 revenue of $25.2M , and +99.8% cumulative change since FY2023) , GAAP net income of -$14.0M, operating cash flow of -$8.2M, and free cash flow of -$8.3M (-18.8% YoY). On the balance sheet, ECOR closed FY2025 with $18.7M in total assets against $6.6M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$32.0M	-$14.0M	-$8.2M	-$8.3M	$18.7M	$6.6M
FY2024 (FY)	2024-12-31	$25.2M	-$11.9M	-$6.9M	-$6.9M	$20.5M	—
FY2023 (FY)	2023-12-31	$16.0M	-$18.8M	-$14.7M	-$14.7M	—	—

3. ECOR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ECOR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, electroCore Inc. (NASDAQ: ECOR) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $8.11 (-3.68% 1D, market cap $73.1M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ECOR ranks #721 in composite RQD confidence.

How does ECOR compare to OM and HYPR in the Health Care sector?

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), ECOR carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of 86.8%, and ROIC of -35.0%. By comparison, OM (Outset Medical Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -28.0%, cap $78.8M) and HYPR (Hyperfine Inc. (Class A)) posts a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $78.9M). Among the 5-stock peer group, ECOR leads on earnings multiple (N/A) while OM leads on capital efficiency (-28.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ECOR?

Per ECOR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001560258), electroCore Inc. generated $32.0M in revenue (+27.2% YoY), -$14.0M in net income, and -$8.3M in free cash flow against $18.7M in total assets and $6.6M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ECOR trading relative to its 50-day, 200-day, and 52-week technical levels?

ECOR last traded at $8.11 (-3.68% on volume of 33,035 shares), positioning the stock -14.54% below its 50-day simple moving average ($9.49) and +4.78% above its 200-day simple moving average ($7.74). Across its 52-week range of $4.41 to $12.70, ECOR sits at the 44.6% percentile with a 14-day RSI of 37.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($7.10 to $9.12).

ECOR Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are ECOR insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies ECOR leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: ECOR RQD Cockpit ECOR 12M Forecast ECOR Earnings & Move ECOR Dividends & DRIP ECOR Insiders & 13F ECOR Whale Options ECOR Profit Sankey ECOR News & Why